Retrospective analysis of the Gram-positive bacteria-infected cases in the Department of Hematology.
10.7534/j.issn.1009-2137.2013.05.041
- Author:
Yu JING
1
;
Jian BO
;
Yu ZHAO
;
Hong-Hua LI
;
Shu-Hong WANG
;
Wen-Rong HUANG
;
Quan-Shun WANG
Author Information
1. Department of Hematology, Chinese PIA General Hospital, Beijing 100853, China. E-mail: jingyu301@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Acetamides;
adverse effects;
therapeutic use;
Adult;
Aged;
Female;
Gram-Positive Bacterial Infections;
diagnosis;
drug therapy;
Humans;
Linezolid;
Male;
Middle Aged;
Oxazolidinones;
adverse effects;
therapeutic use;
Retrospective Studies;
Teicoplanin;
adverse effects;
therapeutic use;
Vancomycin;
adverse effects;
therapeutic use
- From:
Journal of Experimental Hematology
2013;21(5):1291-1295
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to evaluate the efficacy and safety of linezolid, vancomycin and teicoplanin for the treatment of patients infected by Gram-positive bacteria in the Department of Hematology by retrospective analysis. The patients with fever in our department from January to December in 2011 were selected for blood culture with Gram-positive bacteria and treated with linezolid, vancomycin or teicoplanin alone.Various parameters were recorded before and after treatment, such as fever time, respiratory symptoms, physical signs, radiographic changes, blood and biochemical routine, and adverse reactions. The efficacy and safety of linezolid, vancomycin and teicoplanin were compared according to the fever abating time, bacterial clearance rate, clinical efficiencies and adverse events. The patients were divided into linezolid group (15 patients), vancomycin group (17 patients) and teicoplanin group (20 patients). The results showed that the mean time of fever abating in linezolid group was (4.43 ± 3.15)d, bacterial clearance rate and clinical efficiency in linezolid group were 55.56% and 86.67%, respectively. The above three data in vancomycin group were (6.83 ± 4.67)d, 54.54% and 76.47% respectively, and were (5.57 ± 4.16)d, 41.67% and 80.00% in teicoplanin group respectively. There was no statistically significant difference between three groups (P > 0.05). There were one case of diarrhea and two cases of thrombocytopenia in the linezolid group, and one case of nausea and two cases of creatinine increase in the vancomycin group. There were three cases of thrombocytopenia in the teicoplanin group. The thrombocytopenia in five cases and the hemogram drop in patients with leukemia after treatment were overlapped, their drug treatment did not stop, but their thrombocytopoiesis recovered to normal-level, thus the drug treatment were considered as no relation with thrombocytopenia. It is concluded that the treatment efficacy between linezolid, vancomycin and teicoplanin for Gram-positive bacterial infections is not statistically different, but linezolid maybe have advantage over vancomycin and teicoplanin in fever abating time, bacterial clearance rate and clinical efficiency.
